Keros Therapeutics (KROS) Asset Utilization Ratio (2020 - 2025)
Keros Therapeutics posted quarterly Asset Utilization Ratio of 0.45 for Q4 2025, up 225179.88% year-on-year from N/an in Q4 2024, and up 39.4% on a QoQ basis from 0.32 in Q3 2025.
Keros Therapeutics (KROS) has 6 years of Asset Utilization Ratio data on file, last reported at 0.45 in Q4 2025.
- For the quarter ending Q4 2025, Asset Utilization Ratio rose 225179.88% year-over-year to 0.45; the trailing twelve-month figure through Dec 2025 stood at 0.45 (up 225179.88% YoY), and the FY2025 full-year result was 0.51, changed N/A from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.45, up from 0.32 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.45 in Q4 2025 and bottomed at 0.0 in Q4 2024.
- The 5-year median for Asset Utilization Ratio is 0.06 (2022), against an average of 0.12.
- The widest annual swing landed in 2024, when Asset Utilization Ratio slumped 146.3%; it then soared 225179.88% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.07 in 2021, then slipped by 13.25% to 0.06 in 2022, then sank by 99.33% to 0.0 in 2023, then plunged by 146.3% to 0.0 in 2024, then jumped by 225179.88% to 0.45 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.45 (Q4 2025), 0.32 (Q3 2025), and 0.3 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.45 |
| Sep 30, 2025 | 0.32 |
| Jun 30, 2025 | 0.30 |
| Mar 31, 2025 | 0.30 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.00 |
| Dec 31, 2022 | 0.06 |
| Sep 30, 2022 | 0.15 |
| Jun 30, 2022 | 0.16 |
| Mar 31, 2022 | 0.15 |
| Dec 31, 2021 | 0.07 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.05 |
| Mar 31, 2020 | 0.21 |